Navigation Links
EnVivo Pharmaceuticals Announces Reversal of Cognitive Deficits in Alzheimer's Disease Transgenic Mouse Model With Gamma-Secretase Modulator
Date:7/14/2009

VIENNA, July 14 /PRNewswire/ -- EnVivo Pharmaceuticals today announced at the Alzheimer's Association 2009 International Conference on Alzheimer's Disease (ICAD) the reversal of behavioral deficits observed in an Alzheimer's disease transgenic animal model after chronic oral dosing of a proprietary gamma-secretase modulator (GSM). The data was disclosed as part of the preclinical characterization of the development candidate EVP-0962.

EVP-0962 is a proprietary small molecule that belongs to a new generation of potential Alzheimer drugs known as gamma-secretase modulators (GSMs). As a gamma-secretase modulator, EVP-0962 selectively inhibits the production of the toxic AB42 peptide without affecting the total amount of AB. As EVP-0962 does not affect other gamma secretase substrates required for normal function, such as Notch, it is predicted to slow the progression of Alzheimer's disease by reducing the disease-associated toxic AB42 species and to display an intrinsically superior safety profile compared to gamma secretase inhibitors (GSIs).

EVP-0962 selectively reduces the production of AB42 in multiple cell lines and in the brains of normal mice and rats after a single dose. It significantly reduces the production of AB42 in the brains of transgenic mice after two months of daily oral administration. In the same transgenic Alzheimer's disease model, mice developed deficits in the hippocampal memory task known as contextual fear conditioning. Chronic dosing with EVP-0962 reverses these deficits back to normal (wild type) levels. EVP-0962 also displays an excellent safety profile in a 14-day rat toxicology study, confirming suitability for clinical development.

"We are very excited about these findings since they represent to us the first demonstration with a bona fide GSM of functional improvement in an Alzheimer's disease model with concomitant lowering of AB42," said Ke
'/>"/>

SOURCE EnVivo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. EnVivo Pharmaceuticals Announces Executive Appointment
2. Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
3. Poniard Pharmaceuticals Appoints Gary A. Lyons to Board of Directors
4. Cadila Pharmaceuticals Launches Joint Venture With Novavax in India
5. Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity
6. OncoMed Pharmaceuticals Appoints Sunil Patel Senior Vice President, Corporate Development
7. Angiotech Pharmaceuticals, Inc. announces conference call and webcast
8. NeoStem Raises Additional Funds from Principals of Suzhou Erye Pharmaceuticals Company Ltd. and U.S. Institutional and Private Investors, Bringing the Total Recent Financings to Over $15 Million; Funds Will Support Expansion Activities in the United State
9. Rib-X Pharmaceuticals, Inc. Appoints Dr. Russell Greig to Board of Directors
10. OncoGenex Pharmaceuticals Added to Russell Indexes
11. ADVENTRX Pharmaceuticals Announces Plans for Remainder of 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... , Aug. 19, 2014   Synthetic Biologics, ... developing novel anti-infective biologic and drug programs targeting ... announced today that its novel C. difficile ... 54 th Interscience Conference on Antimicrobial Agents ... Washington D.C. Synthetic Biologics, ...
(Date:8/18/2014)... (PRWEB) August 19, 2014 2014 ... Industryā€¯ is a professional and in-depth research report ... basic Linalool information, including its definition, classification, ... industry overview. This research covers the international market ... global industry analysis covering macroeconomic environment & economic ...
(Date:8/18/2014)... FREDERICK, Md. , Aug. 18, 2014 ... the maker of advanced consumer medical devices ... Kotak was interviewed by CEOLIVE.TV as ... The entire interview is available at ... interview Dr. Kotak explains to investors the ...
(Date:8/18/2014)... August 18, 2014 Global HIV Infection ... report announced by Reportstack. The rate of HIV infection and ... a declining note at a positive rate across the globe. ... 2.3 million in 2005 to 1.5 in 2013, with the ... for such drastic changes in the infection rates has been ...
Breaking Biology Technology:Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 4Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 2Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 3Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 4BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 2BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 3Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4
... 2011 Inovio Pharmaceuticals, Inc. (NYSE Amex: ... and preventive vaccines against cancers and infectious diseases, announced ... showed remarkable immune responses in monkeys, following similarly strong, ... data from earlier animal studies. The data was presented ...
... the term "splitsville" usually means "check your prenup." ... from boron nitride nanotubes, "splitsville" could mean "happily ... National Laboratory (Berkeley Lab) and the University of ... University, have developed a technique in which boron ...
... HAYWARD, Calif., June 28, 2011 Intarcia Therapeutics, ... results of a phase 2 clinical study of ... for the treatment of type 2 diabetes at ... San Diego, California. (Logo:   http://photos.prnewswire.com/prnh/20050301/SFTU126LOGO ...
Cached Biology Technology:Inovio Pharmaceuticals' Prostate Cancer DNA Vaccine Demonstrates Strong T Cell Responses in Monkeys; Company on Track for Phase I Clinical Trial 2Inovio Pharmaceuticals' Prostate Cancer DNA Vaccine Demonstrates Strong T Cell Responses in Monkeys; Company on Track for Phase I Clinical Trial 3Inovio Pharmaceuticals' Prostate Cancer DNA Vaccine Demonstrates Strong T Cell Responses in Monkeys; Company on Track for Phase I Clinical Trial 4Inovio Pharmaceuticals' Prostate Cancer DNA Vaccine Demonstrates Strong T Cell Responses in Monkeys; Company on Track for Phase I Clinical Trial 5Inovio Pharmaceuticals' Prostate Cancer DNA Vaccine Demonstrates Strong T Cell Responses in Monkeys; Company on Track for Phase I Clinical Trial 6Splitsville for boron nitride nanotubes 2Splitsville for boron nitride nanotubes 3Splitsville for boron nitride nanotubes 4Intarcia Presents Positive Phase 2 48-week Results From ITCA 650 Study at the American Diabetes Association 71st Scientific Sessions 2Intarcia Presents Positive Phase 2 48-week Results From ITCA 650 Study at the American Diabetes Association 71st Scientific Sessions 3Intarcia Presents Positive Phase 2 48-week Results From ITCA 650 Study at the American Diabetes Association 71st Scientific Sessions 4Intarcia Presents Positive Phase 2 48-week Results From ITCA 650 Study at the American Diabetes Association 71st Scientific Sessions 5
(Date:8/19/2014)... the seas during warm phases and became extinct during ... establishes a link between marine crocodilian diversity and the ... than 140 million years. , The research, led ... France and formerly from the University of Bristol, UK ... Today, crocodiles are ,cold-blooded, animals that mainly live in ...
(Date:8/19/2014)... ever had a glass of fizzy soda knows that ... in a finding with wide industrial applications, Princeton researchers ... down into the liquid as well. , "It is ... we were surprised, and fascinated, to discover that when ... injected tiny oil droplets into the water," said Howard ...
(Date:8/19/2014)... Rochelle, August 19, 2014A new ovoid structure discovered in ... clay, contains a variety of minerals, and shows evidence ... resulting melting of the permafrost and mixing of surface ... broad range of analytical studies to determine the origin ... for how this ovoid formed, point to the most ...
Breaking Biology News(10 mins):Evolution of marine crocodilians constrained by ocean temperatures 2Bubbling down: Discovery suggests surprising uses for common bubbles 2Bubbling down: Discovery suggests surprising uses for common bubbles 3Life on Mars? Implications of a newly discovered mineral-rich structure 2
... Doha, Qatar Urgent law enforcement action by governments ... crucial to addressing the illicit ivory trade, according to ... Detailed regional summaries of the data held in ... database on ivory seizures, highlight the failure of law ...
... ever before of how much radiation reaches sensitive tissues ... models of the human body being developed at the ... of computer simulation tools and 3-D patient models that ... said Wesley E. Bolch, Ph.D., a professor in the ...
... monster movies, but palaeontologists have discovered evidence of how an ... place 4 million years ago. Such fossil evidence ... of bite marks on an otherwise well-preserved dolphin skeleton, the ... that led to the death of the dolphin, and determined ...
Cached Biology News:New analysis points to ivory enforcement failures in parts of Africa, Asia 2Age, gender can affect risk to radiation treatment 2Age, gender can affect risk to radiation treatment 3Jaws -- 4 million BC 2
SpectroQuest single beam 4nm UV/Vis spectrophotometer; stand-alone unit; large angled LCD screen; large sample compartment...
Fluorescence Preserving Media, 100 mL...
... Blunt-Ended PCR Cloning Kit, 40 reactions. ... cloning of all PCR products with ... cloning approaches by offering consistently better ... 25-fold more positive clones.Amplicons generated by ...
... development to targets including proteins and to ... cancer-specific surface antigens. A&Gs service is ... in approximately 40 days (duration may vary ... Phase I: Immunization, test bleed and ...
Biology Products: